

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)***Complete if Known**

Application No.	10/731,465
Filing Date	December 9, 2004
First Named Inventor	Jeffrey A. Whitsett
Art Unit	1632
Examiner Name	Montanari, David A.
Attorney Docket No.	0010872/0507287

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner initials	Cite No.	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	T ⁶
		Country Code ³ -Number ⁴ -Kind code ⁵ (if known)				

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
DA	1	"Supplement Materials and Methods, Animals and Transgene Genotype", JAW-74, May 3, 2004, Science, Suppl., pages 1-11.	
	2	GLASSER, S.W., et al., "Pneumonitis and Emphysema in sp-C Gene Targeted Mice", The Journal of Biological Chemistry, April 18, 2003, pages 14291-14298, Volume 278, No. 16, The American Society for Biochemistry and Molecular Biology, Inc.	
	3	GLASSER, S.W., et al.; "Macrophage Dysfunction and Susceptibility to Pulmonary Pseudomonas Aeruginosa Infection in SP-C Deficient Mice", Children's Hospital Medical Center & the University of Cincinnati College of Medicine.	
	4	LAWSON, W.E., et al.; "Increased and Prolonged Pulmonary Fibrosis in Surfactant Protein C-Deficient Mice Following Intratracheal Bleomycin", American Journal of Pathology, November 2005, pages 1267-1277, Volume 167, No. 5, American Society of Investigative Pathology.	
	5	NOGEE, L.M.; "Abnormal Expression of Surfactant Protein C and Lung Disease", Am. J. Respir. Cell Mol. Biol., 2002, pages 641-644, Volume 26, Internet Address: www.atsjournals.org.	
	6	PARK, K-S, et al.; "SPDEF regulates goblet cell hyperplasia in the airway epithelium", The Journal of Clinical Investigation, April 2007, pages 978-988, Volume 117, Number 4, Internet Address: http://www.jci.org.	
	7	WAN, H., et al.; "Fox a2 regulates alveolarization and goblet cell hyperplasia", Development, November 5, 2003, pages 953-954, Volume 131, The Company of Biologists 2004.	
	8	WAN, H., et al.; "Foxa2 is Required for Transition to Air Breathing at Birth", JAW-74, May 3, 2004, Science, pages 1-21.	
	9	WAN, H., et al.; "Foxa2 Regulates Alveolarization and Goblet Cell Hyperplasia", JAW-67/Development & Disease, October 20, 2003, pages 1-46.	

EXAMINER SIGNATURE

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

